Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 4/20 | 1.00 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.61 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL659130 | 0.98 | IDO1 (1.00) | IDO1LOXL2AKR1C3CA12CA1 | |
| SCHEMBL2351746 | 0.84 | IDO1 (0.72) | IDO1LOXL2AKR1C3CA12CA1 | |
| SCHEMBL37463 | 0.83 | IDO1 (0.70) | IDO1LOXL2AKR1C3CA12CA1 | |
| SCHEMBL8062311 | 0.83 | IDO1 (0.70) | IDO1LOXL2AKR1C3CA12CA1 | |
| SCHEMBL28381661 | 0.80 | IDO1 (0.67) | IDO1LOXL2AKR1C3CA12CA1 | |
| SCHEMBL10546903 | 0.79 | IDO1 (0.65) | IDO1LOXL2AKR1C3RAB9AALDH1A1 | |
| SCHEMBL23091915 | 0.79 | IDO1 (0.66) | IDO1LOXL2AKR1C3CA12CA1 | |
| SCHEMBL4016592 | 0.79 | IDO1 (0.66) | IDO1LOXL2AKR1C3CA12CA1 | |
| SCHEMBL12417032 | 0.79 | IDO1 (0.66) | IDO1LOXL2AKR1C3CA12CA1 | |
| SCHEMBL535425 | 0.79 | IDO1 (0.66) | IDO1LOXL2TSHRALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115362161-B | Process for preparing 3' -O-amino-2 ' -deoxyribonucleoside-5 ' -triphosphate | DNA斯克瑞普特公司 | 2025-03-07 | — | — | CN | claimed |
| CN-117907491-B | Double-derivatization technology-based abasic site LC-MS/MS analysis method | 中国人民解放军军事科学院军事医学研究院 | 2024-06-04 | — | — | CN | claimed |
| CN-117907491-A | Double-derivatization technology-based abasic site LC-MS/MS analysis method | 中国人民解放军军事科学院军事医学研究院 | 2024-04-19 | — | — | CN | claimed |
| CN-115950970-A | HPLC detection method for ketose in aldose | 唐传生物科技（厦门）有限公司 | 2023-04-11 | — | — | CN | claimed |
| CN-115932076-A | Method for detecting ketose in aldose | 唐传生物科技（厦门）有限公司 | 2023-04-07 | — | — | CN | claimed |
| CN-115362161-A | Process for preparing 3' -O-amino-2 ' -deoxyribonucleoside-5 ' -triphosphates | DNA斯克瑞普特公司 | 2022-11-18 | — | — | CN | claimed |
| WO-2022122846-A1 | ETHODS OF DETECTING ALDEHYDES IN SAMPLES | LONZA LTD (CH) | 2022-06-16 | — | — | WO | claimed |
| WO-2022040110-A2 | ALKYLATING AGENT AND COMBINATIONS IN THE TREATMENT OF IMMUNE-RELATED AND LIVER DISEASES, ALZHEIMER'S DISEASES AND FIBROSIS DISEASES | LIU SHENG (US) | 2022-02-24 | — | — | WO | claimed |
| US-20210300961-A1 | METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES | DNA SCRIPT SAS (FR) | 2021-09-30 | — | — | US | claimed |
| US-10725042-B2 | Methods of diagnosing and treating cancer | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-07-28 | — | — | US | claimed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | claimed |
| US-20100267657-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | CASE WESTERN RESERVE UNIVERSITY | 2010-10-21 | — | — | US | claimed |
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009150834-A1 | METHOD FOR PREPARATION OF SUGAR CHAIN SAMPLE, SUGAR CHAIN SAMPLE, AND METHOD FOR ANALYSIS OF SUGAR CHAIN | 住友ベークライト株式会社 (JP) | 2009-12-17 | — | — | WO | claimed |
| US-20090306291-A1 | SUGAR CHAIN-CAPTURING SUBSTANCE AND USE THEREOF | SUMITOMO BAKELITE CO., LTD. (JP) | 2009-12-10 | — | — | US | claimed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | claimed |
| EP-0334590-B1 | 3-(Substituted)-1-carba(dethia)-3-cephems and cephalosporins and a process for production therefor | LILLY CO ELI (US) | 2001-07-04 | — | — | EP | claimed |
| WO-1992007951-A1 | QUANTITATION OF ALDEHYDE-CONTAINING LESIONS IN NUCLEIC ACIDS | KOW YOKE WAH (US) | 1992-05-14 | — | — | WO | claimed |
| EP-0334590-A2 | 3-(Substituted)-1-carba(dethia)-3-cephems and cephalosporins and a process for production therefor | ELI LILLY AND COMPANY (US) | 1989-09-27 | — | — | EP | claimed |
| US-4855418-A | Process for production of ceophalosporins | ELI LILLY AND COMPANY (US) | 1989-08-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300961-A1 | METHOD FOR PREPARING 3'-O-AMINO-2'-DEOXYRIBONUCLEOSIDE-5'-TRIPHOSPHATES | DUT, RNMT, NUDT1 | IDO1 997/4885LOXL2 1605/4885AKR1C3 1004/4885 |
| US-20100267657-A1 | ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER | DNASE1, DNASE1L3, UNG | IDO1 2814/4885LOXL2 3649/4885AKR1C3 2282/4885 |
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885LOXL2 1097/4885AKR1C3 821/4885 |
| US-10725042-B2 | Methods of diagnosing and treating cancer | UNG, NTPCR, GUSB | IDO1 2941/4885LOXL2 1863/4885AKR1C3 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.